Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Toho Zinc, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 94%
5707 Toho Zinc CO.,Ltd. 【J-GAAP】
Earnings ReportToho Zinc CO.,Ltd. <5707> [TSE Prime] announced its financial results after the market closed on February 13th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) significantly dropped 51.0% from the same period last year to 2.10 billion yen.
However, the full-year forecast for consolidated ordinary profit has been revised upward 94.4%, from the previous forecast of 1.80 billion yen to 3.50 billion yen (compared to 3.68 billion yen in the previous period), and the declining rate is expected to decrease from 51.2% to 5.1%.
Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated ordinary profit for the October to March period (second half) is expected to increase 57.0%, from the previous forecast of 2.98 billion yen to 4.68 billion yen (compared to 0.95 billion yen in the same period of the previous year), increasing the growth rate from 3.1 times to 4.9 times.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit surged 2.1 times that of the same period last year, reaching 3.28 billion yen. The operating profit margin improved from 7.4% in the same period last year to 9.9%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 97,321 | -691 | -3,625 | -30,231 | -2,226.6 | ー | Feb 14, 2024 | J-GAAP |
| Apr - Dec, 2024 | 97,295 | 5,877 | 4,299 | -1,017 | -75.0 | 116.5 | Feb 14, 2025 | J-GAAP |
| Apr - Dec, 2025 | 90,103 | 2,913 | 2,106 | 1,731 | 58.6 | 60.2 | Feb 13, 2026 | J-GAAP |
| YoY | -7.4% | -50.4% | -51.0% | - | - |
Guidance Update
Second Half Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2025 Prev | 64,568 | 3,272 | 2,982 | 2,654 | 195.5 | 0 | Nov 13, 2025 | J-GAAP |
| Oct - Mar, 2025 New | 69,168 | 5,472 | 4,682 | 4,054 | 298.6 | 0 | Feb 13, 2026 | J-GAAP |
| Revision Rate | +7.1% | +67.2% | +57.0% | +52.8% | +52.8% |
Full Year Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2026 Prev | 118,400 | 2,600 | 1,800 | 1,300 | 95.7 | 0 | Nov 13, 2025 | J-GAAP |
| Mar, 2026 New | 123,000 | 4,800 | 3,500 | 2,700 | 198.9 | 0 | Feb 13, 2026 | J-GAAP |
| Revision Rate | +3.9% | +84.6% | +94.4% | +107.7% | +107.7% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 62,764 | 2,242 | 953 | -5,666 | -393.3 | 0 | May 15, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 69,168 | 5,472 | 4,682 | 4,054 | 298.6 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | +10.2% | +144.1% | +391.3% | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 130,803 | -690 | -10,727 | -46,452 | -3,421.3 | 0 | May 13, 2024 | J-GAAP |
| Mar, 2025 | 126,267 | 5,625 | 3,689 | -1,458 | -101.2 | 0 | May 15, 2025 | J-GAAP |
| Mar, 2026 Guidance | 123,000 | 4,800 | 3,500 | 2,700 | 198.9 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | -2.6% | -14.7% | -5.1% | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 33,792 | 2,494 | 1,563 | -5,225 | -385.1 | 7.4 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 28,972 | -252 | -610 | -441 | -30.6 | -0.9 | May 15, 2025 | J-GAAP |
| Apr - Jun, 2025 | 26,874 | -853 | -1,078 | -1,111 | -37.6 | -3.2 | Aug 14, 2025 | J-GAAP |
| Jul - Sep, 2025 | 26,958 | 181 | -104 | -243 | -8.2 | 0.7 | Nov 13, 2025 | J-GAAP |
| Oct - Dec, 2025 | 36,271 | 3,585 | 3,288 | 3,085 | 104.5 | 9.9 | Feb 13, 2026 | J-GAAP |
| YoY | +7.3% | +43.7% | +110.4% | - | - |
Related Articles
Retty, Oct-Dec (1Q) Ordinary Profit Turns to Profit
COSMO BIO, Ordinary Profit Unexpectedly Turn to Loss for Last Fiscal Year, 30% Decrease in The Current Fiscal Year
e-LogiT, Apr-Dec (Cumulative 3Q) Net Income Turns to Loss, Oct-Dec Net Income Decreases by 53%
KPP GROUP, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 41%
IID, First Half Ordinary Profit Decreases by 27%, Oct-Dec Ordinary Profit Decreases by 8%
Bridge Consulting, Oct-Dec (1Q) Ordinary Profit Increases by 15%
TAUNS Laboratories, First Half Ordinary Profit Decreases by 52%, Oct-Dec Ordinary Profit Decreases by 5%
Bushiroad, First Half Ordinary Profit Increases by 82%
Medrx, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
GOKURAKUYU, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 0.3%, Oct-Dec Ordinary Profit Decreases by 21%